Novartis Offers $120 Million For Corthera Eyeing Phase III Acute Cardiology Product
Relaxin enables the pharma to expand its reach in acute cardiology as its mega-drug Diovan faces patent expiries.
Relaxin enables the pharma to expand its reach in acute cardiology as its mega-drug Diovan faces patent expiries.